A 48-year-old woman with established type 2 diabetes presented acutely with severe nausea, vomiting, chills, and intense abdominal pain. She became febrile and tachycardic and entered a marked hypertensive crisis within hours of self-administering tirzepatide, a dual GLP-1 receptor agonist. Emergency clinicians initially interpreted the constellation—fever, tachycardia, systemic inflammatory markers, and profound metabolic derangement—as compatible with septic shock. Empiric broad-spectrum antibiotics were therefore started while resuscitative measures were undertaken.
Clinical momentum favored infection early. Cultures and routine infectious workup were sent, and the patient received intravenous fluids and hemodynamic support. The study team reported that clinical features and available laboratory data at presentation mimicked sepsis closely enough to justify that initial treatment pathway.
Despite empiric antimicrobial therapy, cultures returned negative. The authors noted persistent, severe lactic acidosis that seemed disproportionate to the apparent perfusion status. Investigators considered that the hyperlactatemia might represent a catecholamine-driven, type B lactic acidosis rather than classic hypoperfusion-related, type A lactic acidosis. Urinary normetanephrines were elevated, a biochemical signal that redirected the differential toward pheochromocytoma.
The treating team withheld beta-blockade until they achieved adequate alpha-blockade, adhering to standard endocrine precautions for suspected catecholamine-secreting tumors. The source did not provide specific lactate concentrations or precise normetanephrine values in the abstract; those numeric details were not reported in the provided material.
Cross-sectional imaging identified a left adrenal mass containing fat. Radiologic interpretation initially favored myelolipoma because of the fat component, which posed a diagnostic pitfall. The authors emphasized that a fat-containing adrenal lesion does not reliably exclude a functioning pheochromocytoma, and they cautioned against adrenal biopsy when biochemical or clinical suspicion for pheochromocytoma exists.
Functional imaging was planned to further characterize the lesion. The study team arranged outpatient 64Cu-DOTATATE positron emission tomography, signaling the next diagnostic step toward confirming a catecholamine-secreting lesion and local staging before definitive treatment decisions.
Blood pressure control and correction of metabolic abnormalities were central to in-hospital care. Clinicians administered intravenous fluids and a continuous nicardipine infusion for acute blood pressure management; oral doxazosin was started to provide alpha-adrenergic blockade for catecholamine excess. Beta-blockade remained withheld until appropriate alpha-blockade had been established.
Supportive measures included electrolyte correction and close hemodynamic monitoring. The team discontinued empiric antibiotics once infection became unlikely based on negative cultures and evolving clinical data. Over the subsequent 48 hours the patient’s blood pressure and lactate improved, and clinical stabilization permitted de-escalation of intensive therapies.
The patient was discharged on oral alpha-blockade, with plans for outpatient functional imaging and definitive surgical evaluation. The authors identified two practical lessons from this case: consider pheochromocytoma in patients with unexplained lactic acidosis plus hypertensive crisis, and avoid biopsy of adrenal lesions when a functioning tumor is suspected.
The report also raised a temporal association between administration of a GLP-1 receptor agonist (tirzepatide in this instance) and onset of the crisis. The authors described this link as hypothesis-generating; the source did not report mechanistic data, causality, or population-level evidence to confirm that GLP-1 receptor agonists precipitate pheochromocytoma crises. That uncertainty remains an explicit limitation.
Limitations documented in the source include the single-patient case-report design and absence of definitive causal proof linking tirzepatide to the endocrine event. The abstract did not report numeric laboratory values, nor did it include final pathological confirmation of the adrenal lesion within the provided text. Planned outpatient 64Cu-DOTATATE imaging and subsequent surgical evaluation were listed as next steps rather than completed interventions in the presented material.